Skip to content
← Catalog

Cancer Immunol Res 2026 · FAP-CAR via targeted LNP · lymphodepletion-free in vivo · Bajbouj/Puré

"Fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAF), is a promising therapeutic target to achieve normalization of the tumor microenvironment." In vivo strategy: "anti-CD5-conjugated targeted lipid nanoparticles (tLNP) encapsula…

Type
paper
Domain
oncology
Grade
conference
License
LIGHT_HOPE_proprietary
Provenance
m622_verify_wave_2_2026-05-16
evidence_grade
A
category
in_vivo_car_t_lnp_lymphodepletion_free
status
verified
instance_tag
sunvax-antibody-2025
clinical_claim_softening
"preclinical mouse model · NOT human clinical data · not intended to guide individual patient treatment choices"
journal
Cancer Immunology Research
year
2026
authors
Khuloud Bajbouj,Ellen Puré
abstract_snippet
"Fibroblast activation protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAF), is a promising therapeutic target to achieve normalization of the tumor microenvironment." In vivo strategy: "anti-CD5-conjugated targeted lipid nanoparticles (tLNP) encapsu
pmid
41686204
doi
10.1158/2326-6066.CIR-25-0663
View at source ↗

Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.